Columbus Venture Partners creates a new company in
Bizkaia for synthetic DNA production: Syngoi Technologies
Madrid, 5 October 2021. Today Columbus Venture Partners announces the creation of Syngoi
Technologies, a biotechnology company engaged in the production of synthetic DNA through a new
enzymatic process, owned by the company, that addresses the needs of advanced therapies where DNA
is the fundamental starting material. This is the case of gene therapy and mRNA-based vaccines,
emerging therapeutic strategies where manufacturing is an important bottleneck.
Syngoi has its own technology for the manufacture of its optimised synthetic DNA (orDNATM) which
confers multiple advantages over traditional plasmid DNA. On the one hand, it does not require cell
culture infrastructure and production times are reduced. On the other hand, it does not contain bacteria or
antibiotic-resistant genes (relevant aspects for regulatory authorities). In addition, it offers advantages
over other synthetic DNA, since it allows optimising the therapeutic response of the gene of interest, in
accordance with the client’s use requirements, without any technological limitations.